#United States #New York #Class Action #Securities Fraud #Pacira BioSciences

Investors Alert: Class Action Update on Pacira BioSciences

Investors in Pacira BioSciences, Inc., are being reminded of an important class action lawsuit that is currently underway. Law firm Levi & Korsinsky has advised shareholders that the lead plaintiff deadline for filing claims is set for March 14, 2025. This legal action is crucial for anyone affected by the alleged securities fraud that transpired from August 2, 2023, to August 8, 2024.

Case Background

The lawsuit was initiated because of significant concerns regarding Pacira's stock price, which saw a dramatic plunge following an adverse court ruling related to its patent for the medication Exparel. As this product generates around 80% of Pacira's revenue, the implications of the court's decision were severe. On August 9, 2024, Pacira disclosed through a press release that the U.S. Patent No. 11,033,495, pertaining to Exparel, was deemed invalid by the court.

This outcome also opened up doubts about the validity of other patents held by the company, which could lead to increased competition in the market and more significant financial losses. The result of this legal announcement was a staggering drop in share value — from $22.36 per share to $11.70, marking a fall of more than 47% in a single day.

Who Can Participate?

If you experienced financial losses in Pacira BioSciences during the specified timeframe, now is the time to act. Filing as a lead plaintiff is not a requirement to participate in potential recovery from this case. Currently, individuals affected by the stock drop are encouraged to join the class action, which does not require any payment upfront for participation.

Legal Representation

Levi & Korsinsky, LLP is leading this initiative. With a 20-year history of securing substantial compensation amounts for investors, they have proven expertise in complex securities litigation. This firm consistently ranks among the top U.S. securities litigation firms and is dedicated to representing shareholders efficiently and effectively.

If you wish to reach out to Levi & Korsinsky, you can contact attorney Joseph E. Levi via email at [email protected] or by phone at (212) 363-7500. They will guide you through the process of participating in this case with no costs incurred for the class members.

Next Steps

In summary, Pacira shareholders have until March 14, 2025, to position themselves regarding this significant class action lawsuit. Since participation does not come with any financial obligation, it is an opportunity for those affected to seek potential compensation for losses endured.

Stay informed and ensure your interests are represented in this ongoing litigation. For more information or to enroll, visit Levi & Korsinsky’s website.

With the deadline approaching, it’s vital for investors to stay alert and make informed decisions regarding their legal rights and potential claims.

Conclusion

This class action represents an important juncture for Pacira BioSciences investors. Those affected should not miss out on the opportunity to reclaim their losses amidst the ongoing legal battles. As developments unfold, updates will be provided to keep shareholders informed of the proceedings and any necessary actions they might need to undertake.